After years of research and clinical trials, the Multidisciplinary Association for Psychedelic Studies (MAPS) is convincing government officials and patients that the drug can be beneficial in the treatment of Post-Traumatic Stress Disorder (PTSD). MAPS recently announced they had received expanded access approval for the continued research into MDMA-assisted Psychotherapy for PTSD. This is a major step toward making the drug legal for medical purposes.The Food and Drug Administration (FDA) recognition of the drug's effectiveness for trauma survivors furthers the organization's effort. If Phase 3 trials are effective, the therapy will be approved.
"We are looking at possible FDA approval for treatment at the end of 2021, and the accessibility of treatment in clinics by 2022," said Brad Burge, a spokesperson for MAPS.
Results of the research done by MAPS have been encouraging. So encouraging that the results were published in The Lancet Psychiatry in 2018. According to the publication, a study of 26 veterans, firefighters, and police officers with service-related PTSD found that two of the three testing groups responded positively to MDMA-assisted Psychotherapy and had "significantly greater decreases in PTSD symptom severity."
SOURCE: Andrew Keiper, Associate Producer with the Investigative Unit, Fox News